Holen Sie sich die Stockscreener-App
29.40
5.97%
-1.83
Handel nachbörslich:
29.10
-0.30
-1.02%
Schlusskurs vom Vortag:
$31.23
Offen:
$30.1
24-Stunden-Volumen:
803.33K
Relative Volume:
1.14
Marktkapitalisierung:
$3.29B
Einnahmen:
$418.33M
Nettoeinkommen (Verlust:
$-252.07M
KGV:
-12.25
EPS:
-2.4
Netto-Cashflow:
$-238.84M
1W Leistung:
-10.72%
1M Leistung:
-10.47%
6M Leistung:
-6.84%
1J Leistung:
+18.79%
1-Tages-Spanne:
$28.95
$30.10
1-Wochen-Bereich:
$28.95
$33.97
52-Wochen-Spanne:
$23.82
$44.34
Zai Lab Limited Adr Stock (ZLAB) Company Profile
Firmenname
Zai Lab Limited Adr
Sektor
Branche
Telefon
862161632588
Adresse
4560 JINKE ROAD, SHANGHAI
Vergleichen Sie ZLAB mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ZLAB
Zai Lab Limited Adr
|
29.40 | 3.47B | 418.33M | -252.07M | -238.84M | -2.40 |
|
VRTX
Vertex Pharmaceuticals Inc
|
412.22 | 104.45B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
469.36 | 60.95B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
572.60 | 59.11B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
812.95 | 49.23B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
320.94 | 35.92B | 4.56B | -176.77M | 225.30M | -1.7177 |
Zai Lab Limited Adr Stock (ZLAB) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-08-25 | Fortgesetzt | Jefferies | Buy |
| 2025-03-07 | Eingeleitet | Scotiabank | Sector Outperform |
| 2025-03-03 | Herabstufung | BofA Securities | Buy → Neutral |
| 2023-12-14 | Eingeleitet | Morgan Stanley | Overweight |
| 2023-08-10 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2022-01-21 | Eingeleitet | Macquarie | Outperform |
| 2021-10-12 | Eingeleitet | Bernstein | Mkt Perform |
| 2020-04-28 | Eingeleitet | Goldman | Buy |
| 2020-04-15 | Eingeleitet | Guggenheim | Buy |
| 2019-07-12 | Eingeleitet | BofA/Merrill | Buy |
| 2019-07-05 | Eingeleitet | Macquarie | Outperform |
| 2019-01-29 | Eingeleitet | Credit Suisse | Outperform |
| 2018-11-21 | Eingeleitet | Jefferies | Buy |
| 2018-06-21 | Fortgesetzt | Leerink Partners | Outperform |
| 2018-02-14 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2017-10-16 | Eingeleitet | JP Morgan | Neutral |
| 2017-10-16 | Eingeleitet | Leerink Partners | Outperform |
Alle ansehen
Zai Lab Limited Adr Aktie (ZLAB) Neueste Nachrichten
Zai Lab Limited (ZLAB) Moves 21.5% Higher: Will This Strength Last? - MSN
Is Zai Lab's Valuation Justified as Revenue Growth Lags the Biotech Industry (ZLAB)? - Sahm
Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
Zai Lab Limited Announces Equity Incentive Grants to Employees - TipRanks
Zai Lab (NASDAQ:ZLAB) Shares Gap UpStill a Buy? - MarketBeat
Zai Lab Limited Depositary Receipt Stock Analysis and ForecastStochastic Oscillator Alerts & High Profit Trading Signals - Early Times
Analysts Offer Insights on Healthcare Companies: United Therapeutics (UTHR) and Zai Lab (ZLAB) - The Globe and Mail
How robust is Anheuser Busch Inbev SA Sponsored ADR stock financial position2025 Volume Leaders & Free High Return Stock Watch Alerts - newser.com
Zai Lab Limited Investigated Regarding Potential Securities Law ViolationsContact Levi & Korsinsky for DetailsZLAB - ACCESS Newswire
Acadian Asset Management LLC Buys New Shares in Zai Lab Limited Unsponsored ADR $ZLAB - MarketBeat
Levi & Korsinsky Reminds Shareholders of an Investigation into Zai Lab Limited (ZLAB) Regarding Potential Securities Fraud Allegations - ACCESS Newswire
Lost Money on Zai Lab Limited (ZLAB)? Contact Levi & Korsinsky Regarding an Ongoing Investigation - ACCESS Newswire
Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) Receives $56.35 Consensus Price Target from Analysts - MarketBeat
Shareholder Rights Advocates at Levi & Korsinsky Investigate Zai Lab Limited (ZLAB) Regarding Possible Securities Fraud Violations - ACCESS Newswire
Insider Buying: Zai Lab (NASDAQ:ZLAB) Insider Purchases 10,000 Shares of Stock - MarketBeat
Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) Receives $56.35 Average PT from Brokerages - Defense World
Woodline Partners LP Sells 558,781 Shares of Zai Lab Limited Unsponsored ADR $ZLAB - MarketBeat
Zai Lab (NASDAQ:ZLAB) Shares Gap DownTime to Sell? - MarketBeat
Zai Lab Limited ADR (NASDAQ: ZLAB) Is Up 14.37% – Is It Capable Of A Rally? - stocksregister.com
FY2026 EPS Estimates for Zai Lab Reduced by Leerink Partnrs - MarketBeat
Market Sentiment Around Loss-Making Zai Lab Limited (NASDAQ:ZLAB) - 富途牛牛
Raymond James Financial Inc. Boosts Holdings in Zai Lab Limited Unsponsored ADR $ZLAB - MarketBeat
Cubist Systematic Strategies LLC Increases Stake in Zai Lab Limited Unsponsored ADR $ZLAB - MarketBeat
Zai Lab's Double Whammy: Earnings Miss, Phase 3 Setback - Benzinga
Why Zai Lab (ZLAB) Is Down 5.5% After Diminished Final Results for Bemarituzumab in Gastric Cancer - Sahm
Zai Lab FY2026 EPS Forecast Lowered by Leerink Partnrs - Defense World
Canada Pension Plan Investment Board Buys New Shares in Zai Lab Limited Unsponsored ADR $ZLAB - MarketBeat
MPM Bioimpact LLC Acquires 33,659 Shares of Zai Lab Limited Unsponsored ADR $ZLAB - MarketBeat
Frazier Life Sciences Management L.P. Makes New Investment in Zai Lab Limited Unsponsored ADR $ZLAB - MarketBeat
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zai Lab LimitedZLAB - FinancialContent
Raymond James Financial Inc. Has $4.55 Million Holdings in Zai Lab Limited Unsponsored ADR $ZLAB - Defense World
C3.ai Posts Downbeat Results, Joins GitLab, Salesforce… - inkl
C3.ai Posts Downbeat Results, Joins GitLab, Salesforce And Other Big Stocks Moving Lower In Thursday's Pre-Market Session - Benzinga
Zai Lab: to await results of Fortitude-102 prior to reg. filing - AInvest
ZAI LAB Plunges ~13% on Heavy Trading as Amgen's Bemarituzumab Final Analysis Shows Weaker Survival Benefit - AASTOCKS.com
Stocks Showing Rising Market Leadership: Zai Lab ADR Earns 82 RS Rating - Investor's Business Daily
First ADC Therapy for Cervical Cancer: Zai Lab's TIVDAK Gets Hong Kong Regulatory Green Light - Stock Titan
Zai Lab Announces Approval of TIVDAK® for Patients with Recurrent or Metastatic Cervical Cancer in Hong Kong - Business Wire
Zai Lab Limited Unsponsored ADR $ZLAB Shares Purchased by Invesco Ltd. - Defense World
How high can Zai Lab Limited Depositary Receipt stock goTrade Signal Summary & Risk Adjusted Buy and Sell Alerts - Newser
Zai Lab Announces Participation in Investor Conferences in June 2025 - FinancialContent
Zai Lab Limited Depositary Receipt stock chart pattern explained2025 Geopolitical Influence & Weekly Breakout Watchlists - Newser
Can trapped investors hope for a rebound in Zai Lab Limited Depositary Receipt2025 Year in Review & Low Risk High Reward Trade Ideas - Newser
Should you hold or exit Zai Lab Limited Depositary Receipt now2025 Technical Overview & Free Fast Entry Momentum Trade Alerts - Newser
Predicting Zai Lab Limited Depositary Receipt trend using moving averagesProduct Launch & Reliable Price Action Trade Plans - Newser
Price momentum metrics for Zai Lab Limited Depositary Receipt explainedJuly 2025 Gainers & Capital Protection Trading Alerts - Newser
Nuveen LLC Makes New $3.27 Million Investment in First Advantage Co. $FA - Defense World
Zai Lab Announces Participation in Investor Conferences in September 2025 - The Globe and Mail
Russell Investments Group Ltd. Sells 193,978 Shares of Zai Lab Limited Unsponsored ADR $ZLAB - Defense World
Zai Lab to Participate in Investor Conferences in September 2025 - AInvest
Amazon.com, Inc. $AMZN Shares Purchased by Woodard & Co. Asset Management Group Inc. ADV - Defense World
Finanzdaten der Zai Lab Limited Adr-Aktie (ZLAB)
Umsatz
Nettogewinn
Free Cashflow
ENV
5.47%
1.59%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):